• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Effect of decoction of Fuzheng Jiedu Xiaoji formula (扶正解毒消積方) plus chemoembolization on primary liver cancer in patients

    2022-07-20 15:54:08WUTongYANGZhiyunYANGYuyingJIANGYuyongMENGPeipeiLIUHuiminTIANYehongZHANGQiaoli
    關(guān)鍵詞:消積扶正

    WU Tong,YANG Zhiyun,YANG Yuying,JIANG Yuyong,MENG Peipei,LIU Huimin,TIAN Yehong,ZHANG Qiaoli

    WU Tong,YANG Zhiyun,YANG Yuying,JIANG Yuyong,MENG Peipei,LIU Huimin,Department of Integrated Traditional Chinese and Western Medicine,Beijing Ditan Hospital,Capital Medical University,Beijing 100015,China

    TIAN Yehong,Acupuncture and Minimally Invasive Oncology,The Third Affiliated Hospital,Beijing University of Chinese Medicine,Beijing 100029,China;Institute of Acupuncture and Moxibustion,Shaanxi University of Chinese Medicine,Shaanxi 712046,China

    ZHANG Qiaoli,Acupuncture and Minimally Invasive Oncology,The Third Affiliated Hospital,Beijing University of Chinese Medicine,Beijing 100029,China

    Abstract OBJECTIVE:To investigate the effect of the decoction of Fuzheng Jiedu Xiaoji formula (扶正解毒消積方,FJXF)plus chemoembolization (TACE) on primary liver cancer(PLC) in patients,and study the underlying mechanism.METHODS:Patients with PLC who met the inclusion criteria were randomized into case group and control group.The case group was treated with FJXF combined with TACE.The control group was treated with TACE alone.The short-term clinical effect was evaluated;liver biochemistry,liver function index and multidrug resistance-associated indicators were detected.RESULTS:FJXF combined with TACE in the case group significantly increased the disease control rate than TACE alone in the control group (83.3% vs 61.1%).There was a reduction in the serum alpha-fetoprotein at 8 weeks after treatment in each group,while no difference between the two groups.The same trend can be observed for transaminase and direct bilirubin in both groups.In the case group,it showed a significant increase for albumin at 8 weeks after treatment,while no change in the control group.Multidrug resistanceassociated indicators for multidrug resistance protein 1 and p-glycoprotein were upregulated in the case group but remained stable in the control group.CONCLUSIONS:FJXF combined TACE had a better short-term effect than TACE alone in patients with PLC.The potential mechanism was probably associated with alleviated multidrug resistance induced by FJXF.Additionally,FJXF didn’t increase the risk of liver damage in the combined therapy.

    Keywords:liver neoplasms;ATP binding cassette transporter,subfamily B,member 1;chemoembolization,therapeutic;Fuzheng Jiedu Xiaoji formula

    1.INTRODUCTION

    Primary liver cancer (PLC) is a common malignancy,particularly in China.Global cancer statistics indicated that PLC was the sixth most commonly diagnosed cancer and the fourth leading cause of cancer death worldwide in 2018,with about 841 000 new cases and 782 000 deaths.1The American Cancer Society estimated that in 2020 there was 42 810 new cases and 30 160 deaths of PLC.2China has a high incidence of PLC accounting for 46.6% new cases and 47.1% deaths.1Therefore,active prevention and treatment are of great significance for PLC.However,due to the insidious onset and rapid progression of PLC,only 30% patients benefited in surgical resection and liver transplantation.Most patients have no opportunity of surgery after first diagnosed,they are only treated with palliative care intervention,such as transcatheter arterial chemoembolization (TACE),radiofrequency ablation,cryoablation or molecular targeted drugs.Furthermore,current treatment for PLC did not significantly improve 5-year survival in which multi-drug resistance is an important factor of treatment failure.3Fuzheng Jiedu Xiaoji formula (扶正解毒消積方,FJXF) from Traditional Chinese Medicine (TCM) is a clinically effective empirical prescription of the Center for Integrative Medicine of Beijing Ditan hospital.Our previous clinical study indicated that integrative therapy based on FJXF can control the progression and improve the survival rate for PLC.4Based on the previous studies,this study investigated the clinical effect of FJXF combined with TACE for PLC and elucidated the potential mechanism from the phenotype of multi-drug resistance.

    2.METHODS

    2.1.Patients

    A total of 72 patients with PLC admitted to Beijing Ditan hospital from July 2017 to December 2018 were eligible for the study.The included patients were randomized into case group and control group by random number table in the ratio of 1∶1.The details about baseline demographic and clinical characteristics in the two groups are shown in Table 1.There was no significant difference between the two groups on the baseline data(P >0.05).The study was approved by the Ethics Committee of Beijing Ditan Hospital (Jing Di Lun Ke Zi(2017) No.(011)-01).

    Table 1 Baseline information of the patients between the two groups

    2.2.Inclusion criteria

    (a) Conformed to the diagnostic criteria of“Chinese Society of Clinical Oncology Guidelines for the Diagnosis and Treatment of Primary Liver Cancer”;5(b)unresectable PLC according to the“2018 practice guidance by the American Association for the Study of Liver Diseases”;6(c) Karnofsky performance score (KPS)≥ 70;(d) aged 35 to 65 years;(e) life expectancy > 3 months;(f) Child-Pugh class A or class B;(g) patients signed the informed consent.

    2.3.Exclusion criteria

    (a) Extrahepatic metastases or other primary malignancies;(b) received chemoradiotherapy before enrolled;(c) uncontrollable serious infection,long-term chronic infection or non-healed wound;(d) critical diseases in heart,lung,kidney or other organs;(e)patients with mental disorder;(f) pregnant or lactating women;(g) had contraindications of arterial embolism;(h) patients unable to cooperate.

    2.4.Treatments

    The patients were treated with TACE alone in the control group and FJXF combined TACE in the case group.

    The operation of TACE is as follows:Seldinger technique was used to insert the catheter through the right femoral artery into the hepatic artery,then the blood supply artery of the tumor was observed with mesenteric angiography.Next,chemotherapeutic drug perfusion was completed after superselection of the blood supply artery of the lesion.Chemotherapeutic drugs included fluorouracil (Shenyang Pharmaceutical Co.,Ltd.,Shenyang,China,500 mg/m2) and Epirubicin (Pfizer S.r.l.,Wuxi,China,40 mg/ m2).Finally,perfusion tissue was embolized with iodized oil,and the embolization was further strengthened with gelatin sponge debris till blood flow slowed down.The dose of the embolization was determined according to the tumor size and vascular density.7,8

    FJXF was taken orally on the first day after TACE treatment.FJXF consisted of Dangshen (Radix Codonopsis) 20 g,Huangqi (Radix Astragali Mongolici) 20 g,Baizhu (Rhizoma Atractylodis Macrocephalae) 15 g,Fuling (Poria) 15 g,Beishashen (Radix Glehniae) 15 g,Maidong (Radix Ophiopogonis Japonici) 15 g,Danggui(Radix Angelicae Sinensis) 15 g,Shudihuang (Radix Reh-manniae Preparata) 15 g,Wugong (Scolopendra)10 g,Qiyeyizhihuagen (Rhizoma Paridis) 15 g and Biejia(Carapax Trionycis) 15 g.The formula was modified with clinical symptoms.Dosages and schedules are as follows:decocted in water for oral administration at a dose of 200 mL twice per day,with 14 d as a cycle for 4 consecutive cycles.It was provided and decocted by the TCM pharmacy of Beijing Ditan Hospital Capital Medical University.

    2.5.Reagents

    Reverse transcription-polymerase chain reaction (RTPCR) kit was from TaKaRa Biotechnology Co.,Ltd.,(Dalian,China,3587A),and rabbit anti-human Pglycoprotein monoclonal antibody was purchased from Jackson ImmunoResearch Laboratories Inc.,(PA,USA,111-035-003).

    2.6.Experimental methods

    Real-time PCR:total RNA was extracted and the firststrand cDNA was synthesized by RT-PCR Kit instructions.The PCR was carried out in a 25 μL reaction system.Glyceraldehyde-3-phosphate dehydrogenase was used as an internal reference,and the ratio was used as the multidrug resistance protein 1 (MDR1) mRNA expression.MDR1 upstream primer was 5’-GGCCTAATGCCGAACACATT-3’,and downstream primer was 5’-CTTCTTCACCTCCAGGCTCA -3’.

    Western blot:the specimens were added with protein lysate,homogenized,placed on ice for 15 min,and centrifuged at 12 000 rpm for 10 min.Then the supernatant was pipetted,loaded to the lane,and separated by electrophoresis,transferred to PVDF membrane for incubation with primary antibody at 4℃overnight,then reacted with secondary antibody at room temperature for 4 h.After that,the specimens were examined with X-ray.Finally,the images were scanned and analyzed using LabWorks software.

    2.7.Observation indicators

    (a) The evaluation of short-term clinical effect according to Response Evaluation Criteria in Solid Tumors(RECIST) 1.1.Complete response (CR) defined as complete disappearance of tumor for more than 4 weeks.Partial response (PR) defined as a decrease of ≥ 30% in the sum of the longest diameter for more than 4 weeks.Stable disease (SD) defined as a reduction of < 30% or increase of < 20% in the sum of the longest diameter.Progressive disease (PD) defined as an increase of ≥ 20%in the sum of the longest diameter or occurrence of new lesions.9Disease control rate (DCR) describes the percentage of patients with advanced cancer in which therapeutic intervention has led to a complete response,partial response,or stable disease.The formula of DCR is as follows:

    (b) Liver-associated biochemistry and function parameters in peripheral blood included alanine aminotransferase (ALT),aspartate transferase (AST),alpha-fetoprotein (AFP),direct bilirubin (DBIL),prealbumin (PAB),albumin (ALB) and international standardized ratio of coagulation (INR).The parameters were detected before treatment,at 1 week and 8 weeks after treatment.

    (c) Indicators associated with multidrug resistance in peripheral venous blood involved in MDR1 and pglycoprotein (P-gp),which were detected before treatment and 8 weeks after treatment,respectively.

    2.8.Statistical analysis

    SPSS statistics (version 22.0) was used for data analysis.The count data was expressed as percentage (%) with χ2test.The measurement data were expressed by mean ±standard deviation () witht-test.A threshold ofPvalue was set at 0.05.

    3.RESULTS

    3.1.Comparison of short-term clinical effect between the two groups

    The DCR was 83.3% in the case group and 61.1% in the control group.There was a significant difference between the two groups (Table 2).

    3.2.Comparison of liver-associated biochemistry and function

    The serum ALT,AST and DBIL levels increased at 1 week after the treatment and returned to pre-treatment levels at 8 weeks after the treatment in each group.Meanwhile,they had no difference between the two groups.AFP decreased significantly at 8 weeks after treatment in each group,while it didn’t show a more significant decrease between case and control group.As to the PBA,there was no change after treatment in the case group,while in the control group it was significantly increased at 1 week after TACE,then returned to pretreatment level at 8 weeks after the treatment.Serum ALB level had no difference at 1 week after treatment in each group.Interestingly,there was a significant elevation for ALB at 8 weeks after treatment in the case group but not in the control group.INR remained stable at all times in each group (Table 3).

    Table 2 Comparison of the short-term clinical effect between the two groups [n (%)]

    Table 3 Comparison of liver biochemistry/function before and after treatment

    3.3.Comparison of MDR1 mRNA expression in both groups

    Before treatment,there was no difference for MDR1 expression between case group and control group.In the case group,the mRNA expression of MDR1 slightly decreased at 8 weeks after treatment compared with before treatment (1.10 ± 0.08vs1.03 ± 0.10,P> 0.05).In the control group,the mRNA expression of MDR1 significantly increased at 8 weeks after treatment compared with before treatment (1.08 ± 0.09vs1.30 ±0.07,P< 0.05).

    3.4.Comparison of P-gp protein expression between in both groups

    Before treatment,there was no difference of P-gp expression between case group and control group.In the case group,P-gp kept unchanged at 8 weeks after treatment compared with before treatment (0.59 ± 0.05vs0.60 ±0.06,P> 0.05).In the control group,P-gp significantly increased at 8 weeks after treatment than before treatment (0.58 ± 0.06vs0.82 ± 0.08,P< 0.05) (Figure 1).

    Figure 1 The protein expression of P-gp detected by Western blot in both groups

    4.DISCUSSION

    There is a high incidence for PLC in China accounting for almost half of worldwide cases.Due to the diversity for risk factors,individual variability and tumor heterogeneity,early diagnosis for PLC is limited.Therefore,most patients are diagnosed in advanced stage with poor therapeutic effect.Although some progress has been made for hepatic arterial chemoembolization,minimally invasive treatment and molecular targeted therapies,the 5-year survival rate for PLC was only 10.1%.10-12

    TCM plays an important role in the treatment of refractory disease,such as cancer.In recent years,the combined treatment of TCM and western medicine for malignant tumors has been widely accepted.In Chinese ancient literature,PLC can be classified into the"accumulation","hypochondriac pain",or“l(fā)iver accumulation".According to the theory of TCM,PLC is induced by long-term combined effects of internal and external factors.The internal factors mainly include liver dysfunction leaded by emotional depression and spleen dysfunction induced by fatigue.The external factors mainly include dampness and heat invading in the liver and gallbladder to form toxicity and stasis.Therefore,the pathogenesis for PLC is characterized with the deficiency complicated with excess so that it is difficult to cure.FJXF,which is the clinically effective empirical prescription of the Center for Integrative Medicine of Beijing Ditan hospital,consists of Dangshen (Radix Codonopsis),Huangqi (Radix Astragali Mongolici),Baizhu (Rhizoma Atractylodis Macrocephalae),etc.The formula has the effects of benefiting qi and blood,promoting blood circulation,removing blood stasis,and softening hardness to dissipate stagnation.A Metaanalysis evaluated the effectiveness and safety of multiple treatments (including TACE combined with TCM,TACE combined with sorafenib,TACE or sorafenib alone) for patients with advanced liver cancer,and the results showed that TACE combined with TCM had the best effect and the lowest incidence of adverse events than other treatments.13In a previous clinical study,we had investigated the effect of the integrative therapy based on FJXF for PLC.The results showed that it can delay disease progression and improve survival rate in patients with PLC.4Consistently,the results in this study showed that the DCR of FJXF combined with TACE in the treatment of patients with PLC was 83.3%and was significantly higher than that of TCEA alone(61.1%).Besides,a previous study found that TACE combined with TCM treatment was beneficial to patients with PLC in improving AST,DBIL,ALB and AFP.14Our study indicated that the levels of ALT,AST and DBIL in both case group and control group were increased transiently at 1 week after treatment,then returned to pre-treatment level at 8 weeks after treatment,which were similar to other studies.15-17Therefore,FJXF didn’t increase risk of liver damage in the combined therapy.As to the hepatic synthetic function,ALB in the case group at 8 weeks after treatment was significantly elevated.We speculated that the treatment of FJXF based on the TACE may be beneficial to the improvement of liver synthetic ability.

    TACE is one of the common treatment methods for patients with advanced liver cancer.This method can achieve a median survival of 11-20 months,however more than 40% of patients with PLC have poor therapeutic effect.18One of critical reasons is the multidrug resistance of hepatoma cell to chemotherapeutic drugs.19-21The overexpression of MDR1 and its encoded protein P-gp is the main causes of tumor resistance.P-gp is the most important member of the ABC transporter family,which can actively pump the hydrophobic drug against the concentration gradient from the inside to the outside of the cell in an ATP energy-dependent manner.22,23Drug resistance of hepatoma cell can also be induced by pumping chemotherapeutic drugs out of the cancer cells.The results of our study showed that the expression of both MDR1 and P-gp significantly increased in the control group after treatment,while kept stable in the case group.It suggests that TACE induced multidrug resistance.Importantly,FJXR alleviated TACE-induced multidrug resistance by the stable expression of MDR1 and P-gp,which is also one of the mechanisms for better therapeutic effect in the treatment of FJXF combined with TACE.

    The results of this study showed that FJXF combined with TACE has a better effect in the treatment of unresectable patients with PLC.Its potential mechanism is probably associated with the stable expression of MDR1 and P-gp through avoiding acquired multidrug resistance induced by TACE treatment.Meanwhile,this combination therapy is convenient for clinical application and universal availability.

    5.REFERENCES

    1.Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin 2018;68:394-424.

    2.Siegel RL,Miller KD,Jemal A.Cancer statistics,2020.CA Cancer J Clin 2020;70:7-30.

    3.Zhou X,Ding J,Li H,et al.Hedgehog signalling mediates drug resistance through targeting TAP1 in hepatocellular carcinoma.J Cell Mol Med 2020;24:4298-311.

    4.Gu LL,Liu HM,Zhou XB,et al.Efficacy analysis of integrative therapy based on Fuzheng Jiedu Xiaoji formula for primary liver cancer.J Tradit Chin Med 2014;55:576-9.

    5.Zhou J,Sun HC,Wang Z,et al.Guidelines for diagnosis and treatment of primary liver cancer in China (2017 Edition).LIVER CANCER 2018;7:235-260

    6.Marrero JA,Kulik LM,Sirlin CB,et al.Diagnosis,staging,and management of hepatocellular carcinoma:2018 practice guidance by the American Association for the Study of Liver Diseases.Hepatol 2018;68:723-50.

    7.Grandhi MS,Kim AK,Ronnekleiv-Kelly SM,et al.Hepatocellular carcinoma:from diagnosis to treatment.Surg Oncol 2016;25:74-85.

    8.Han K,Kim JH.Transarterial chemoembolization in hepatocellular carcinoma treatment:Barcelona clinic liver cancer staging system.World J Gastroenterol 2015;21:10327-35.

    9.Schwartz LH,Litiere S,de Vries E,et al.RECIST 1.1-Update and clarification:grom the RECIST committee.Eur J Cancer 2016;62:132-7.

    10.Fu J,Wang H.Precision diagnosis and treatment of liver cancer in China.Cancer Lett 2018;412:283-8.

    11.Lurje I,Czigany Z,Bednarsch J,et al.Treatment strategies for hepatocellular carcinoma -a multidisciplinary approach.Int J Mol Sci 2019;20.

    12.Cyranoski D.China embraces precision medicine on a massive scale.Nat 2016;529:9-10.

    13.Chen QF,Wu PH,Huang T,et al.Efficacy of treatment regimens for advanced hepatocellular carcinoma:a network Meta-analysis of randomized controlled trials.Medicine (Baltimore) 2019;98:e17460.

    14.Wan YM,Li YH,Xu ZY,et al.The effect of transarterial chemoembolization in combination with Kang’ai injection on patients with intermediate stage hepatocellular carcinoma:a prospective study.Integr Cancer Ther 2017;17:477-85.

    15.Chen J,Zhang SL.Study of liver function impairment after TACE in liver cancer.Shi Yong Lin Chuang Yi Yao Za Zhi 2017;21:202-4.

    16.Ma MX,Sun XL,Guo YG,et al.Effect of TACE on liver function indexes in patients with primary liver cancer.Hainan Yi Xue Yuan Xue Bao 2017;23:1705-8.

    17.Zhang SW,Lan Y,Sun YM.Effect of hepatic artery chemoembolization on hepatic function in the treatment of hepatic malignancy.Lin Chuang Yi Yao Wen Xian Za Zhi 2017;4:1011.

    18.Martin S,Fako V,Dang H,et al.PKM2 inhibition may reverse therapeutic resistance to transarterial chemoembolization in hepatocellular carcinoma.J Exp Clin Cancer Res 2020;39.

    19.Buschauer S,Koch A,Wiggermann P,et al.Hepatocellular carcinoma cells surviving doxorubicin treatment exhibit increased migratory potential and resistance to doxorubicin re-treatmentin vitro.Oncol Lett 2018;15:4635-40.

    20.Perez-Tomas R.Multidrug resistance:retrospect and prospects in anti-cancer drug treatment.Curr Med Chem 2006;13:1859-76.

    21.Song JE,Kim DY.Conventionalvsdrug-eluting beads transarterial chemoembolization for hepatocellular carcinoma.World J Hepatol 2017;9:808-14.

    22.Roninson IB.The role of the MDR1 (P-glycoprotein) gene in multidrug resistancein vitroandin vivo.Biochem Pharmacol 1992;43:95-102.

    23.Tian QE,De LH,Yan M,et al.Effects of Astragalus polysaccharides on P-glycoprotein efflux pump function and protein expression in H22 hepatoma cellsin vitro.BMC Com-plement Altern Med 2012;12:94.

    猜你喜歡
    消積扶正
    基于自噬探討芪靈扶正清解方抗抑郁作用研究
    Fuzheng Kang' ai decoction (扶正抗癌方) inhibits cell proliferation,migration and invasion by modulating mir-21-5p/human phosphatase and tensin homology deleted on chromosome ten in lung cancer cells
    消積飲治療肺癌的研究概況
    養(yǎng)正消積方劑治療惡性腫瘤作用機制的研究進(jìn)展
    疑難病雜志(2020年2期)2020-12-17 09:17:30
    健脾消積湯治療小兒厭食癥的臨床療效觀察
    畫說中醫(yī)
    UPLC-MS/MS法同時測定貞芪扶正膠囊中10種成分
    中成藥(2017年7期)2017-11-22 07:33:04
    消積散結(jié)丸聯(lián)合血栓通注射液治療脾切術(shù)后門靜脈血栓19例
    扶正解毒湯聯(lián)合調(diào)強放療治療宮頸癌50例
    FOLFOX聯(lián)合健脾消積合劑治療晚期胃癌60例臨床觀察
    精品国产国语对白av| 午夜精品国产一区二区电影| 亚洲美女黄片视频| 精品久久久久久久毛片微露脸| 精品福利观看| av欧美777| 日日爽夜夜爽网站| av福利片在线| 日韩 欧美 亚洲 中文字幕| 99久久综合精品五月天人人| 久久中文看片网| 久久午夜亚洲精品久久| 男女午夜视频在线观看| 日日摸夜夜添夜夜添小说| 禁无遮挡网站| 成人三级黄色视频| xxx96com| 青草久久国产| 一进一出好大好爽视频| 精品久久蜜臀av无| 国产精品久久久av美女十八| 国产精品自产拍在线观看55亚洲| 久久久久精品国产欧美久久久| 伊人久久大香线蕉亚洲五| 欧美日本亚洲视频在线播放| 欧美日韩乱码在线| 俄罗斯特黄特色一大片| 国产精品一区二区免费欧美| 国产免费av片在线观看野外av| 久久国产亚洲av麻豆专区| 国产一区二区激情短视频| 国产免费男女视频| 日韩一卡2卡3卡4卡2021年| 久久精品影院6| 国产aⅴ精品一区二区三区波| 不卡一级毛片| 久久久久九九精品影院| 黑人巨大精品欧美一区二区mp4| 欧美色视频一区免费| 欧美黄色片欧美黄色片| 天天躁夜夜躁狠狠躁躁| 国产高清videossex| 久久久国产成人精品二区| 又黄又粗又硬又大视频| 97超级碰碰碰精品色视频在线观看| 香蕉国产在线看| 精品免费久久久久久久清纯| 在线免费观看的www视频| 日韩欧美国产一区二区入口| 精品国产超薄肉色丝袜足j| 熟妇人妻久久中文字幕3abv| 久久青草综合色| 国产精品一区二区在线不卡| 亚洲av电影不卡..在线观看| 亚洲人成伊人成综合网2020| 国产亚洲av嫩草精品影院| 两个人视频免费观看高清| 久久国产乱子伦精品免费另类| 老汉色∧v一级毛片| 看黄色毛片网站| 久久影院123| 一区在线观看完整版| 国产成人精品在线电影| 久久欧美精品欧美久久欧美| 超碰成人久久| 在线播放国产精品三级| 精品熟女少妇八av免费久了| 久久人妻熟女aⅴ| 国产欧美日韩一区二区三| 黄色 视频免费看| 国产成人免费无遮挡视频| 亚洲成国产人片在线观看| 视频在线观看一区二区三区| 欧美老熟妇乱子伦牲交| 亚洲精品中文字幕在线视频| 国产精品 欧美亚洲| av网站免费在线观看视频| 亚洲成人国产一区在线观看| 欧美日本亚洲视频在线播放| 日韩精品青青久久久久久| 国产精品综合久久久久久久免费 | 午夜亚洲福利在线播放| 精品一品国产午夜福利视频| 国产精品久久久av美女十八| 久久久久亚洲av毛片大全| 丝袜在线中文字幕| 国产午夜福利久久久久久| 精品少妇一区二区三区视频日本电影| 欧美乱色亚洲激情| 免费一级毛片在线播放高清视频 | 国产真人三级小视频在线观看| 搞女人的毛片| svipshipincom国产片| 国产熟女午夜一区二区三区| 天天添夜夜摸| 欧美在线黄色| 在线观看www视频免费| 亚洲av成人一区二区三| 免费少妇av软件| 日韩国内少妇激情av| 国产单亲对白刺激| 视频在线观看一区二区三区| 啦啦啦 在线观看视频| 国产真人三级小视频在线观看| 亚洲成人免费电影在线观看| 日韩大尺度精品在线看网址 | 国产99久久九九免费精品| 在线观看免费午夜福利视频| 波多野结衣av一区二区av| 天天一区二区日本电影三级 | 九色国产91popny在线| 国产av又大| 国产91精品成人一区二区三区| 侵犯人妻中文字幕一二三四区| 中文字幕av电影在线播放| 亚洲成a人片在线一区二区| 深夜精品福利| 婷婷六月久久综合丁香| 在线观看免费视频网站a站| 中文字幕人成人乱码亚洲影| 美女免费视频网站| 日本五十路高清| av中文乱码字幕在线| 日本免费一区二区三区高清不卡 | 国产成人精品在线电影| 90打野战视频偷拍视频| 久久中文字幕人妻熟女| 日本免费a在线| 日日干狠狠操夜夜爽| cao死你这个sao货| 人成视频在线观看免费观看| 亚洲av熟女| 一个人观看的视频www高清免费观看 | 欧美激情极品国产一区二区三区| 国产精品一区二区三区四区久久 | 欧美激情久久久久久爽电影 | 国产一区二区激情短视频| 亚洲精品国产精品久久久不卡| 国产私拍福利视频在线观看| 国产精品,欧美在线| 91麻豆精品激情在线观看国产| 久久中文看片网| 亚洲av成人av| 国产精品日韩av在线免费观看 | 精品日产1卡2卡| 欧美另类亚洲清纯唯美| 亚洲avbb在线观看| 精品久久久久久成人av| 欧美日韩亚洲国产一区二区在线观看| 午夜成年电影在线免费观看| svipshipincom国产片| 最新美女视频免费是黄的| 国内精品久久久久精免费| 热re99久久国产66热| 咕卡用的链子| 欧美性长视频在线观看| 精品福利观看| 一边摸一边做爽爽视频免费| 亚洲熟女毛片儿| 国产一级毛片七仙女欲春2 | 天天一区二区日本电影三级 | 丝袜美腿诱惑在线| 欧美成人性av电影在线观看| 亚洲黑人精品在线| 国内毛片毛片毛片毛片毛片| 午夜a级毛片| 亚洲人成网站在线播放欧美日韩| 国产av一区在线观看免费| 久久亚洲真实| 国产精品一区二区三区四区久久 | 黄色视频,在线免费观看| 亚洲欧美日韩无卡精品| 免费无遮挡裸体视频| 成人18禁高潮啪啪吃奶动态图| 超碰成人久久| 国产精华一区二区三区| 国产亚洲欧美在线一区二区| 一a级毛片在线观看| 他把我摸到了高潮在线观看| 欧美黑人欧美精品刺激| 免费高清视频大片| 变态另类丝袜制服| 丝袜美腿诱惑在线| 麻豆av在线久日| 禁无遮挡网站| 久久久精品国产亚洲av高清涩受| 极品人妻少妇av视频| 91麻豆av在线| 亚洲天堂国产精品一区在线| 久久 成人 亚洲| 在线观看舔阴道视频| 欧美不卡视频在线免费观看 | 国产精品日韩av在线免费观看 | 国产成人免费无遮挡视频| 咕卡用的链子| 激情在线观看视频在线高清| 在线观看免费视频日本深夜| 久久久久久人人人人人| 国产三级在线视频| 午夜a级毛片| 亚洲第一青青草原| 色综合站精品国产| 国产一区二区三区综合在线观看| 在线天堂中文资源库| 大陆偷拍与自拍| 午夜福利在线观看吧| 国产av又大| 女人被狂操c到高潮| 国产aⅴ精品一区二区三区波| 国产99久久九九免费精品| 亚洲专区字幕在线| 一区二区三区激情视频| 精品电影一区二区在线| 人人妻人人澡欧美一区二区 | 国产成人av教育| 在线av久久热| 天堂影院成人在线观看| 精品卡一卡二卡四卡免费| 亚洲专区字幕在线| 亚洲三区欧美一区| av中文乱码字幕在线| 精品一品国产午夜福利视频| 变态另类丝袜制服| 日日干狠狠操夜夜爽| 青草久久国产| 久久精品国产99精品国产亚洲性色 | 一级片免费观看大全| 精品欧美国产一区二区三| 成人国语在线视频| 九色国产91popny在线| 91在线观看av| 日本黄色视频三级网站网址| 久久久久亚洲av毛片大全| 午夜福利一区二区在线看| 淫秽高清视频在线观看| av超薄肉色丝袜交足视频| 中国美女看黄片| 免费在线观看黄色视频的| 成熟少妇高潮喷水视频| 黄色a级毛片大全视频| 在线国产一区二区在线| 精品少妇一区二区三区视频日本电影| 91成人精品电影| 18禁国产床啪视频网站| 成人免费观看视频高清| 国产精品 国内视频| 18禁黄网站禁片午夜丰满| 一卡2卡三卡四卡精品乱码亚洲| 国产精品一区二区免费欧美| 国产伦一二天堂av在线观看| 国产精品免费视频内射| 精品电影一区二区在线| 日韩欧美一区二区三区在线观看| 19禁男女啪啪无遮挡网站| 亚洲九九香蕉| 美女高潮喷水抽搐中文字幕| 日韩欧美免费精品| 禁无遮挡网站| √禁漫天堂资源中文www| 看免费av毛片| 又紧又爽又黄一区二区| 午夜免费成人在线视频| 美女高潮喷水抽搐中文字幕| 丝袜美腿诱惑在线| 99精品久久久久人妻精品| 成人亚洲精品av一区二区| 色播在线永久视频| 九色亚洲精品在线播放| 最好的美女福利视频网| 午夜福利,免费看| 男女下面插进去视频免费观看| 一进一出抽搐动态| 午夜久久久久精精品| 欧美性长视频在线观看| 999久久久国产精品视频| 宅男免费午夜| 最近最新中文字幕大全免费视频| 日韩有码中文字幕| 亚洲avbb在线观看| 亚洲国产日韩欧美精品在线观看 | а√天堂www在线а√下载| 这个男人来自地球电影免费观看| 夜夜夜夜夜久久久久| 脱女人内裤的视频| 九色亚洲精品在线播放| 亚洲自拍偷在线| 日韩三级视频一区二区三区| 一边摸一边抽搐一进一小说| 老司机午夜福利在线观看视频| 亚洲色图综合在线观看| 日本黄色视频三级网站网址| av欧美777| 免费观看人在逋| 国产国语露脸激情在线看| 久久久久久久久免费视频了| 国产精品国产高清国产av| 日韩精品青青久久久久久| 在线免费观看的www视频| 欧美成人性av电影在线观看| 十分钟在线观看高清视频www| 午夜免费鲁丝| 国产精品一区二区精品视频观看| 精品久久久久久,| videosex国产| 高清毛片免费观看视频网站| 亚洲国产中文字幕在线视频| 国产免费男女视频| 黑人巨大精品欧美一区二区蜜桃| 国产精品一区二区三区四区久久 | 欧美+亚洲+日韩+国产| 亚洲av成人av| 中亚洲国语对白在线视频| 欧美丝袜亚洲另类 | 日韩精品青青久久久久久| 丰满的人妻完整版| 国产精品久久久久久人妻精品电影| 精品欧美国产一区二区三| 9色porny在线观看| 亚洲成人免费电影在线观看| 精品国产美女av久久久久小说| 亚洲av电影在线进入| 欧美日韩一级在线毛片| 天堂影院成人在线观看| 曰老女人黄片| 成人三级黄色视频| 叶爱在线成人免费视频播放| 非洲黑人性xxxx精品又粗又长| 欧美久久黑人一区二区| av免费在线观看网站| 亚洲片人在线观看| 黄频高清免费视频| 久久这里只有精品19| 国产精品野战在线观看| 999久久久精品免费观看国产| 免费av毛片视频| 男女下面插进去视频免费观看| av片东京热男人的天堂| 桃色一区二区三区在线观看| 久久热在线av| 少妇 在线观看| 欧美在线黄色| а√天堂www在线а√下载| 99久久精品国产亚洲精品| 午夜日韩欧美国产| 日本免费一区二区三区高清不卡 | e午夜精品久久久久久久| 亚洲国产欧美网| 亚洲av成人不卡在线观看播放网| 国产一区二区在线av高清观看| 亚洲成av人片免费观看| www.熟女人妻精品国产| 曰老女人黄片| 欧美黑人精品巨大| 夜夜爽天天搞| 亚洲avbb在线观看| 欧美精品亚洲一区二区| 日韩 欧美 亚洲 中文字幕| 久久久久久久精品吃奶| 日本在线视频免费播放| 97人妻天天添夜夜摸| 国产主播在线观看一区二区| 满18在线观看网站| 一卡2卡三卡四卡精品乱码亚洲| 欧美乱色亚洲激情| 波多野结衣av一区二区av| 制服丝袜大香蕉在线| 欧美黄色淫秽网站| 免费在线观看视频国产中文字幕亚洲| 男女午夜视频在线观看| 91av网站免费观看| 日本撒尿小便嘘嘘汇集6| 99久久99久久久精品蜜桃| av中文乱码字幕在线| 黑丝袜美女国产一区| 欧美日韩福利视频一区二区| 91大片在线观看| 亚洲 欧美 日韩 在线 免费| 日韩欧美三级三区| 一夜夜www| 操美女的视频在线观看| 午夜日韩欧美国产| 精品国产超薄肉色丝袜足j| 国产欧美日韩精品亚洲av| 国产熟女午夜一区二区三区| 真人做人爱边吃奶动态| 村上凉子中文字幕在线| 欧美激情高清一区二区三区| 91麻豆av在线| 国产精品免费视频内射| 国产精品,欧美在线| 午夜免费激情av| 淫妇啪啪啪对白视频| 成人亚洲精品一区在线观看| 操出白浆在线播放| 丝袜美足系列| 人人妻,人人澡人人爽秒播| 亚洲av电影在线进入| 欧美日韩福利视频一区二区| 亚洲中文日韩欧美视频| 欧美激情 高清一区二区三区| 一区在线观看完整版| 丁香六月欧美| 村上凉子中文字幕在线| 亚洲一码二码三码区别大吗| 国内久久婷婷六月综合欲色啪| 午夜两性在线视频| 亚洲久久久国产精品| 黄色片一级片一级黄色片| 成人永久免费在线观看视频| 国产在线观看jvid| 亚洲精品久久国产高清桃花| 夜夜躁狠狠躁天天躁| 日本免费一区二区三区高清不卡 | 天堂影院成人在线观看| 成人av一区二区三区在线看| videosex国产| 国产成人欧美在线观看| 欧美精品啪啪一区二区三区| 男人舔女人下体高潮全视频| 日本 欧美在线| 怎么达到女性高潮| 97碰自拍视频| 久久人妻熟女aⅴ| 亚洲国产中文字幕在线视频| 久久国产精品影院| 国产私拍福利视频在线观看| 如日韩欧美国产精品一区二区三区| 中文字幕久久专区| 亚洲国产欧美日韩在线播放| 久久精品人人爽人人爽视色| 亚洲成a人片在线一区二区| 曰老女人黄片| 国产精品一区二区三区四区久久 | 在线观看免费视频网站a站| 国产精华一区二区三区| 精品高清国产在线一区| 欧美在线黄色| 免费看十八禁软件| 50天的宝宝边吃奶边哭怎么回事| 大型黄色视频在线免费观看| 一级毛片精品| 91在线观看av| 亚洲伊人色综图| 久久中文字幕人妻熟女| 少妇的丰满在线观看| 久久精品亚洲精品国产色婷小说| 精品一品国产午夜福利视频| 高清毛片免费观看视频网站| 中文字幕av电影在线播放| 伊人久久大香线蕉亚洲五| 黄频高清免费视频| 伦理电影免费视频| 欧美日韩黄片免| 免费女性裸体啪啪无遮挡网站| 国产成人啪精品午夜网站| 欧美亚洲日本最大视频资源| 国产精品自产拍在线观看55亚洲| 亚洲国产精品久久男人天堂| 久久婷婷成人综合色麻豆| 黑丝袜美女国产一区| 多毛熟女@视频| 18禁观看日本| 国产精品久久久久久人妻精品电影| 亚洲欧美日韩高清在线视频| 天天躁狠狠躁夜夜躁狠狠躁| 成人手机av| 女人爽到高潮嗷嗷叫在线视频| 国产精品香港三级国产av潘金莲| 久久九九热精品免费| 中文字幕高清在线视频| 亚洲第一av免费看| 久久午夜亚洲精品久久| 熟妇人妻久久中文字幕3abv| 午夜福利,免费看| 久久精品国产99精品国产亚洲性色 | 亚洲欧美精品综合久久99| 亚洲欧美日韩高清在线视频| 精品人妻1区二区| a在线观看视频网站| 亚洲国产欧美网| 婷婷六月久久综合丁香| 青草久久国产| 亚洲欧洲精品一区二区精品久久久| 麻豆久久精品国产亚洲av| 国产精品,欧美在线| 亚洲人成电影观看| 午夜福利影视在线免费观看| 久久精品国产亚洲av香蕉五月| 国产成人一区二区三区免费视频网站| 日韩精品中文字幕看吧| 啦啦啦 在线观看视频| 国产麻豆成人av免费视频| 国产精品1区2区在线观看.| 久久精品人人爽人人爽视色| 亚洲第一电影网av| 精品人妻1区二区| 国产精华一区二区三区| 国产亚洲精品一区二区www| 欧美黄色片欧美黄色片| 国产精品亚洲av一区麻豆| 久热爱精品视频在线9| 露出奶头的视频| 级片在线观看| 天天躁狠狠躁夜夜躁狠狠躁| 亚洲色图 男人天堂 中文字幕| 国产精品乱码一区二三区的特点 | 午夜福利成人在线免费观看| 国产精品综合久久久久久久免费 | x7x7x7水蜜桃| 精品不卡国产一区二区三区| 香蕉丝袜av| 高潮久久久久久久久久久不卡| 999精品在线视频| 中亚洲国语对白在线视频| 精品久久久久久久人妻蜜臀av | 亚洲熟妇熟女久久| 日本三级黄在线观看| 黑人巨大精品欧美一区二区蜜桃| 午夜免费激情av| 久久精品国产综合久久久| 十八禁网站免费在线| 熟女少妇亚洲综合色aaa.| 国产高清视频在线播放一区| 免费观看人在逋| 午夜免费鲁丝| 他把我摸到了高潮在线观看| 操美女的视频在线观看| 久久婷婷成人综合色麻豆| 母亲3免费完整高清在线观看| 久久久久久久久中文| 国产精品二区激情视频| www国产在线视频色| 男人舔女人的私密视频| 一本久久中文字幕| 超碰成人久久| 日韩视频一区二区在线观看| 欧美大码av| 午夜福利欧美成人| 免费在线观看亚洲国产| 老汉色∧v一级毛片| 日本 欧美在线| 黑人操中国人逼视频| 亚洲熟妇熟女久久| 黄色丝袜av网址大全| 精品久久久久久,| 精品无人区乱码1区二区| 国产99白浆流出| 亚洲一码二码三码区别大吗| 午夜日韩欧美国产| 人人妻人人爽人人添夜夜欢视频| 欧美日韩亚洲国产一区二区在线观看| 亚洲美女黄片视频| 可以在线观看的亚洲视频| 亚洲欧美精品综合一区二区三区| 亚洲欧美一区二区三区黑人| 91九色精品人成在线观看| 99热只有精品国产| 欧美日韩亚洲国产一区二区在线观看| 此物有八面人人有两片| 如日韩欧美国产精品一区二区三区| 国产精品98久久久久久宅男小说| 亚洲欧美一区二区三区黑人| 男男h啪啪无遮挡| 人人妻人人爽人人添夜夜欢视频| 国产片内射在线| 亚洲精品久久成人aⅴ小说| 99久久国产精品久久久| 在线观看免费视频日本深夜| 亚洲黑人精品在线| 欧美 亚洲 国产 日韩一| 亚洲精品国产精品久久久不卡| 久久影院123| 欧美午夜高清在线| 免费久久久久久久精品成人欧美视频| 久久人人精品亚洲av| 国产极品粉嫩免费观看在线| 久久精品91蜜桃| 一个人观看的视频www高清免费观看 | 国产不卡一卡二| 十分钟在线观看高清视频www| 久久久久亚洲av毛片大全| 中文字幕人妻熟女乱码| 妹子高潮喷水视频| 人成视频在线观看免费观看| 色婷婷久久久亚洲欧美| 一夜夜www| 欧美 亚洲 国产 日韩一| 成在线人永久免费视频| 色播在线永久视频| av有码第一页| 啦啦啦韩国在线观看视频| 欧美激情 高清一区二区三区| 天堂影院成人在线观看| 一进一出好大好爽视频| 成人18禁在线播放| 欧美黑人精品巨大| 国产成人啪精品午夜网站| 亚洲片人在线观看| 欧美日韩亚洲国产一区二区在线观看| 亚洲国产毛片av蜜桃av| 亚洲人成伊人成综合网2020| 久久人人97超碰香蕉20202| 国产精华一区二区三区| 国产亚洲av高清不卡| 丝袜人妻中文字幕| 亚洲中文字幕日韩| 色精品久久人妻99蜜桃| 久热爱精品视频在线9| 国产精品 国内视频| 777久久人妻少妇嫩草av网站| 欧美在线一区亚洲| 好看av亚洲va欧美ⅴa在| 亚洲九九香蕉| 久久精品国产综合久久久| 俄罗斯特黄特色一大片|